170 related articles for article (PubMed ID: 35759904)
41. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
[TBL] [Abstract][Full Text] [Related]
42. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
[TBL] [Abstract][Full Text] [Related]
43. Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study.
Etemadifar M; Abhari AP; Nouri H; Salari M; Maleki S; Amin A; Sedaghat N
BMC Neurol; 2022 Feb; 22(1):64. PubMed ID: 35193507
[TBL] [Abstract][Full Text] [Related]
44. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.
Dillon P; Siadimas A; Roumpanis S; Fajardo O; Fitovski K; Jessop N; Whitley L; Muros-Le Rouzic E
Mult Scler Relat Disord; 2023 Mar; 71():104512. PubMed ID: 36716576
[TBL] [Abstract][Full Text] [Related]
45. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
[TBL] [Abstract][Full Text] [Related]
46. Low degree of cortical pathology is associated with benign course of multiple sclerosis.
Calabrese M; Favaretto A; Poretto V; Romualdi C; Rinaldi F; Mattisi I; Morra A; Perini P; Gallo P
Mult Scler; 2013 Jun; 19(7):904-11. PubMed ID: 23069877
[TBL] [Abstract][Full Text] [Related]
47. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
48. Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS.
Sorensen PS; Kopp TI; Joensen H; Olsson A; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2021 May; 50():102813. PubMed ID: 33578207
[TBL] [Abstract][Full Text] [Related]
49. Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic.
Todorović S; Vojinović S; Savić D; Aleksić D; Danilović M
Acta Neurol Belg; 2024 Apr; 124(2):447-455. PubMed ID: 37962785
[TBL] [Abstract][Full Text] [Related]
50. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis.
Piñar Morales R; Ramírez Rivas MA; Barrero Hernández FJ
Neurologia (Engl Ed); 2021; 36(9):698-703. PubMed ID: 34103271
[TBL] [Abstract][Full Text] [Related]
51. Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: A 5 year prospective cohort study.
Bawand R; Ghiasian M; Fathoallahi N; Moradi A
Mult Scler Relat Disord; 2022 Jul; 63():103857. PubMed ID: 35597079
[TBL] [Abstract][Full Text] [Related]
52. Exploring physicians' prescribing behavior in patients with multiple sclerosis in Saudi Arabia: a sequential explanatory mixed-methods.
Al-Omar HA; Alsowaida N; Aldosari L; Mayet A; Bunyan R; Aljumah M
BMC Neurol; 2023 Mar; 23(1):135. PubMed ID: 37004011
[TBL] [Abstract][Full Text] [Related]
53. [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].
Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Edan G
Rev Neurol (Paris); 2006 Feb; 162(2):185-94. PubMed ID: 16518258
[TBL] [Abstract][Full Text] [Related]
54. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
Juto A; Fink K; Al Nimer F; Piehl F
Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
[TBL] [Abstract][Full Text] [Related]
55. Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry.
Braune S; Rossnagel F; Dikow H; Bergmann A;
BMJ Open; 2021 Aug; 11(8):e042480. PubMed ID: 34344670
[TBL] [Abstract][Full Text] [Related]
56. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis.
Pasca M; Forci B; Mariottini A; Mechi C; Barilaro A; Massacesi L; Repice AM
Mult Scler Relat Disord; 2021 Jan; 47():102591. PubMed ID: 33142245
[TBL] [Abstract][Full Text] [Related]
57. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
[TBL] [Abstract][Full Text] [Related]
58. Untreated patients with multiple sclerosis: A study of French expert centers.
Moisset X; Fouchard AA; Pereira B; Taithe F; Mathey G; Edan G; Ciron J; Brochet B; De Sèze J; Papeix C; Vermersch P; Labauge P; Defer G; Lebrun-Frenay C; Moreau T; Laplaud D; Berger E; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Créange A; Camdessanché JP; Bakchine S; Maurousset A; Hankiewicz K; Pottier C; Maubeuge N; Dimitri Boulos D; Nifle C; Vukusic S; Clavelou P;
Eur J Neurol; 2021 Jun; 28(6):2026-2036. PubMed ID: 33650261
[TBL] [Abstract][Full Text] [Related]
59. Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Abdel-Mannan OA; Manchoon C; Rossor T; Southin JC; Tur C; Brownlee W; Byrne S; Chitre M; Coles A; Forsyth R; Kneen R; Mankad K; Ram D; West S; Wright S; Wassmer E; Lim M; Ciccarelli O; Hemingway C; Hacohen Y;
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34021056
[TBL] [Abstract][Full Text] [Related]
60. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
